CurrentCignaPolicy N/A

PRIOR AUTHORIZATION POLICY

Policy Summary

PayerCigna

PolicyPRIOR AUTHORIZATION POLICY

Policy CodePolicy N/A

Change Typeclarified

Effective DateJan 21, 2026

Next Review Date

Key ActionPrior authorization is recommended for oral iron chelators; approvals are provided for 1 year and initial approval requires prescription by or in consultation with a hematologist.

SourceLink

POLICY UPDATE CHANGES

Policy updated with review date 01/21/2026 and minor verbiage change in prior revisions (e.g., wording 'benefiting from therapy' phrasing).

5Named products covered

1 yearApproval duration

>1,000Ferritin threshold (transfusion-related)

>300Ferritin threshold (non-transfusion-dependent)

Defines prior authorization requirements, clinical criteria, documentation, approval durations, and exclusions for oral iron chelators (Exjade, Jadenu/Jadenu Sprinkle, Ferriprox tablets and oral solution) for Cigna-administered health benefit plans. Covered as medically necessary with criteria for FDA-approved indications and certain supported uses; prior authorization is recommended and approvals are granted for 1 year. Initial approval requires the agent to be prescribed by or in consultation with a hematologist and documentation of required laboratory thresholds is required where specified.

Thresholds and Approval Duration

Serum ferritin — transfusion-related> 1,000 mcg/L

Serum ferritin — non-transfusion-dependent thalassemia> 300 mcg/L

Liver iron concentration (when applicable)>= 5 mg iron per gram liver dry weight

Approval duration1 year

Medical-Necessity Criteria — Deferasirox (Exjade, Jadenu/Sprinkle)

Deferasirox (Exjade, Jadenu/Sprinkle) Coverage

Covered as medically necessary for FDA-approved indications when criteria below are met. Approvals granted for 1 year.

ANY of the following

1. Iron Overload, Chronic - Transfusion-Related (Initial Therapy)
- i: Patient is receiving blood transfusions at regular intervals for a chronic condition (examples: thalassemia syndromes, myelodysplastic syndrome, chronic anemia, sickle cell disease).
- ii: Prior to starting chelating therapy, serum ferritin level was > 1,000 mcg/L.> 1,000 mcg/L
  Documentation required
- iii: Medication is prescribed by or in consultation with a hematologist.
  Prescriber specialty documentation required
1. Iron Overload, Chronic - Transfusion-Related (Continuation Therapy)
- i: Patient is currently receiving deferasirox.
- ii: Patient is benefiting from therapy, according to the prescriber.
  Examples: reduction in serum ferritin levels, stable disease, reduced organ iron load
2. Iron Overload, Chronic - Non-Transfusion-Dependent Thalassemia Syndromes (Initial Therapy)
- i: Prior to starting chelating therapy, serum ferritin level was > 300 mcg/L.> 300 mcg/L
  Documentation required
- ii: Medication is prescribed by or in consultation with a hematologist.
  Prescriber specialty documentation required
2. Iron Overload, Chronic - Non-Transfusion-Dependent Thalassemia Syndromes (Continuation Therapy)
- i: Patient is currently receiving deferasirox.
- ii: Patient is benefiting from therapy, according to the prescriber.
  Examples: reduction in serum ferritin levels, stable disease, reduced organ iron load

Boxed Warnings: Deferasirox products have boxed warnings regarding renal failure, hepatic failure, and gastrointestinal hemorrhage.

Medical-Necessity Criteria — Deferiprone (Ferriprox tablets and oral solution)

Deferiprone (Ferriprox tablets and oral solution) Coverage

Covered as medically necessary for FDA-approved indications and other uses with supportive evidence when criteria below are met. Approvals granted for 1 year.

ANY of the following

1. Iron Overload, Chronic - Transfusion-Related Due to Thalassemia Syndromes (Initial Therapy)
- i: Prior to starting chelating therapy, serum ferritin level was > 1,000 mcg/L.> 1,000 mcg/L
  Documentation required
- ii: Medication is prescribed by or in consultation with a hematologist.
  Prescriber specialty documentation required
1. Iron Overload, Chronic - Transfusion-Related Due to Thalassemia Syndromes (Continuation Therapy)
- i: Patient is currently receiving deferiprone.
- ii: Patient is benefiting from therapy, according to the prescriber.
  Examples: reduction in serum ferritin levels, stable disease, reduced organ iron load
2. Iron Overload, Chronic - Transfusion-Related Due to Sickle Cell Disease or Other Anemias (Initial Therapy)
- i: Prior to starting chelating therapy, serum ferritin level was > 1,000 mcg/L.> 1,000 mcg/L
  Documentation required
- ii: Medication is prescribed by or in consultation with a hematologist.
  Prescriber specialty documentation required
2. Iron Overload, Chronic - Transfusion-Related Due to Sickle Cell Disease or Other Anemias (Continuation Therapy)
- i: Patient is currently receiving deferiprone.
- ii: Patient is benefiting from therapy, according to the prescriber.
  Examples: reduction in serum ferritin levels, stable disease, reduced organ iron load
3. Other Uses with Supportive Evidence - Non-Transfusion-Dependent Thalassemia Syndromes (Initial Therapy)
- i: Prior to starting chelating therapy, serum ferritin level was > 300 mcg/L.> 300 mcg/L
  Documentation required
- ii: Medication is prescribed by or in consultation with a hematologist.
  Prescriber specialty documentation required
3. Other Uses with Supportive Evidence - Non-Transfusion-Dependent Thalassemia Syndromes (Continuation Therapy)
- i: Patient is currently receiving deferiprone.
- ii: Patient is benefiting from therapy, according to the prescriber.
  Examples: reduction in serum ferritin levels, stable disease, reduced organ iron load

Boxed Warnings: Deferiprone products have a boxed warning regarding the risk of neutropenia and fatal agranulocytosis.

Provider Actions

Prior Authorization

Prior authorization required

Prior authorization is recommended for oral iron chelators; approvals are provided for 1 year. Initial approval requires the medication to be prescribed by or in consultation with a hematologist or a physician specializing in the condition being treated.

Approvals are for 1 year
Initial approval requires prescription by or in consultation with a hematologist or other specialist for the condition

Documentation Required

Documentation of ferritin required

Documentation is required showing serum ferritin thresholds prior to initiation: > 1,000 mcg/L for transfusion-related indications and > 300 mcg/L for non-transfusion-dependent thalassemia. Acceptable documentation may include chart notes, prescription claims records, prescription receipts, and other patient-specific records with identifiers.

Ferritin > 1,000 mcg/L for transfusion-related indications
Ferritin > 300 mcg/L for non-transfusion-dependent thalassemia
Acceptable documentation: chart notes, prescription claims records, prescription receipts, or other patient-specific records with identifying information

Documentation Required

Prescriber specialty documentation

Medication must be prescribed by or in consultation with a hematologist; documentation of the prescriber specialty or consultation is required for initial approval.

Document that medication was prescribed by or in consultation with a hematologist or physician specializing in the condition

Documentation Required

Evidence of benefit for continuation

For patients currently receiving therapy, the provider must document that the patient is benefiting from therapy according to the prescriber.

Reduction in serum ferritin
Stable disease
Reduced organ iron load

Background & Evidence

Oral iron chelators (deferasirox and deferiprone) are indicated for treatment of chronic iron overload from repeated transfusions and for some non-transfusion-dependent thalassemia syndromes. Deferasirox (Exjade, Jadenu/Sprinkle) is indicated for chronic transfusional iron overload in patients ≥ 2 years and for non-transfusion-dependent thalassemia in patients ≥ 10 years with liver iron concentration ≥ 5 mg Fe/g dry weight and serum ferritin > 300 mcg/L. Deferiprone tablets (Ferriprox) are indicated for transfusional iron overload in thalassemia, sickle cell disease, or other anemias in patients ≥ 8 years, while Ferriprox oral solution is indicated for the same transfusional indications in patients ≥ 3 years. Documentation of transfusion-related ferritin thresholds (typically > 1,000 mcg/L for transfusion-related indications and > 300 mcg/L for non–transfusion-dependent thalassemia) and prescriber specialty are required per policy.

Definitions

Evidence

Exjade	deferasirox tablets for suspension (Novartis, generic)
Jadenu	deferasirox tablets (Novartis, generic)
Jadenu Sprinkle	deferasirox oral granules (Novartis, generic)
Ferriprox	deferiprone tablets (Chiesi, generic)
Ferriprox Oral Solution	deferiprone oral solution (Chiesi)

OpenPayer

PRIOR AUTHORIZATION POLICY

Coverage Summary

Medical-Necessity Criteria — Deferasirox (Exjade, Jadenu/Sprinkle)

Medical-Necessity Criteria — Deferiprone (Ferriprox tablets and oral solution)

Not Medically Necessary / Exclusions

Coding

Provider Actions

Background & Evidence

Revision History